Q1 Earnings Forecast for ACRV Issued By HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Acrivon Therapeutics in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.63) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Several other equities research analysts have also issued reports on ACRV. Cantor Fitzgerald restated an “overweight” rating on shares of Acrivon Therapeutics in a research note on Wednesday. KeyCorp assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Acrivon Therapeutics has an average rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Stock Performance

Shares of ACRV stock opened at $2.52 on Friday. The firm has a market cap of $78.46 million, a price-to-earnings ratio of -0.93 and a beta of 0.85. Acrivon Therapeutics has a 52 week low of $2.44 and a 52 week high of $11.90. The firm’s 50-day simple moving average is $5.42 and its two-hundred day simple moving average is $6.57.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.06.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Acrivon Therapeutics in the fourth quarter valued at approximately $40,000. Wealthedge Investment Advisors LLC purchased a new stake in Acrivon Therapeutics in the 4th quarter worth approximately $65,000. Corton Capital Inc. purchased a new stake in Acrivon Therapeutics in the 4th quarter worth approximately $73,000. American Century Companies Inc. grew its position in shares of Acrivon Therapeutics by 14.2% during the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after purchasing an additional 2,186 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares in the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.